Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeMD’s telehealth empire spans virtual visits, HIPAA-bound data flows, nutritional supplements, and a WorkSimpli software arm—so its SEC documents are naturally dense. Finding subscriber churn rates, telemedicine margin trends, or the cost of HIPAA compliance in a 300-page report is a genuine challenge.
Stock Titan solves that problem the moment a filing hits EDGAR. Our AI-powered summaries turn a fresh 10-K annual report into plain-English highlights, while real-time alerts flag every LifeMD insider trading Form 4 transactions. Need the latest LifeMD quarterly earnings report 10-Q filing? It’s here alongside “LifeMD 8-K material events explained,” complete with red-lined changes and KPIs. Investors often search “LifeMD SEC filings explained simply” or “understanding LifeMD SEC documents with AI”; this page answers both by pairing raw PDFs with side-by-side interpretations.
Dive deeper: compare segment revenue between Telehealth and WorkSimpli without scrolling through footnotes, monitor LifeMD executive stock transactions Form 4 in real time, or review the “LifeMD proxy statement executive compensation” to see how bonuses hinge on subscriber growth. Whether you’re after a quick “LifeMD earnings report filing analysis” or a line-item from the “LifeMD annual report 10-K simplified,” our platform keeps every filing type—8-K, S-3, DEF 14A—updated instantly. Complex healthcare disclosures, made clear and actionable.
LifeMD, Inc. (LFMD) director Calum Archibald MacRae filed a Form 4 disclosing a non‑derivative grant of 22,365 restricted shares on 10/02/2025. The filing shows 38,865 total shares beneficially owned by the reporting person after the transaction. The restricted shares have a vesting condition: they vest on 06/01/2026. The transaction was reported on 10/06/2025 with a reported price of $0, consistent with a grant rather than an open‑market purchase.
LifeMD director Roberto Simon received 22,365 restricted stock units on 10/02/2025, increasing his beneficial ownership to 183,175 shares. The Form 4 shows the units were granted at a $0 price and are recorded as non‑derivative common stock awards.
The filing specifies the granted awards are restricted stock units that vest on
FAQ
What is the current stock price of Lifemd (LFMD)?
What is the market cap of Lifemd (LFMD)?
